ACET - Aceto Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.1345
0.0000 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.1345
Open0.1590
Bid0.0000 x 4000
Ask0.0000 x 800
Day's Range0.1330 - 0.1650
52 Week Range0.1300 - 4.2400
Volume6,849,395
Avg. Volume4,301,574
Market Cap4.148M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateFeb 1, 2019 - Feb 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • GlobeNewswire8 hours ago

    ACETO Completes the Sale of Rising Pharmaceuticals

    PORT WASHINGTON, N.Y., April 22, 2019 -- ACETO Corporation (Nasdaq: ACETQ), an international company engaged in the development, marketing, sale and distribution of Human.

  • GlobeNewswire7 days ago

    ACETO to Sell its Chemicals Business Assets to New Mountain Capital

    ACETO Corporation (ACETQ), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has agreed to sell its chemicals business assets to an affiliate of New Mountain Capital (“NMC”), a leading growth-oriented investment firm with over $20 billion in assets under management. The asset purchase agreement was entered into following the conclusion of a court-supervised sale process conducted under Section 363 of the U.S. Bankruptcy Code. Under that process, an asset purchase agreement between Aceto and NMC was executed, dated February 18, 2019, to sell the chemical business assets as the “stalking horse agreement”.

  • GlobeNewswire10 days ago

    ACETO Receives Court Approval of “Stalking Horse” Agreement to Sell Rising Pharmaceuticals to Shore Suven Pharma, Inc.

    ACETO Corporation (ACETQ), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has received approval from the U.S. Bankruptcy Court  to sell the assets of Rising Pharmaceuticals and Rising’s subsidiaries to Shore Suven Pharma, Inc. for gross cash proceeds of $15 million, plus the assumption of operating liabilities and customer obligations related to the acquired business, on a cash-free and debt-free basis. The sale was conducted through a Court-supervised process under Section 363 of the Bankruptcy Code.  Under that process, Shore Suven Pharma’s purchase agreement served as the “stalking horse agreement” and an auction would have been conducted had the Company received qualified offers from other bidders reflecting potentially higher and/or otherwise better terms.

  • 6 Poorly Performing Stocks
    GuruFocus.comlast month

    6 Poorly Performing Stocks

    The return on equity of -211.13% and return on assets of -41.80% are underperforming 84% of companies in the Global Drug Manufacturers - Specialty and Generic industry. The company's largest guru shareholder is Jim Simons (Trades, Portfolio)' Renaissance Technologies with 4.75% of outstanding shares, followed by Chuck Royce (Trades, Portfolio) with 1.53%. The return on equity of -0.71% and return on assets of -0.42% are underperforming 72% of companies in the Global Coal industry.

  • The Wall Street Journallast month

    [$$] Palm Restaurant Family Feud Moves to Bankruptcy Court

    The company that holds The Palm Restaurant’s trademarks filed for bankruptcy in a bid to reach a deal over disputed royalty payments among descendants of the 93-year-old steakhouse’s chain’s founders.

  • The Wall Street Journallast month

    [$$] Generic Drug Distributor Aceto Finds Bidder for Subsidiary

    Corp., the generic drug distributor that filed for bankruptcy last month, has found a bidder for its subsidiary, Rising Pharmaceuticals Inc. Shore Suven Pharma Inc. has agreed to pay $15 million for Rising and its subsidiaries, Aceto said, subject to higher or better offers at auction.

  • GlobeNewswire2 months ago

    ACETO Enters into “Stalking Horse” Agreement to Sell Rising Pharmaceuticals

    ACETO Corporation (ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has entered into a “stalking-horse” asset purchase agreement with Shore Suven Pharma, Inc. to sell the assets of Rising Pharmaceuticals and Rising’s subsidiaries for gross cash proceeds of $15 million, plus the assumption of operating liabilities and customer obligations related to the acquired business on a cash-free and debt-free basis. Shore Suven Pharma, Inc. is a joint venture between Suven Life Sciences Limited, an India-based provider of contract research and manufacturing services for the global life sciences industry, and Shore Pharma Investments, LLC, a company founded by Vimal Kavuru to acquire generic drug assets.

  • ACCESSWIRE2 months ago

    Watch These Four Healthcare Stocks Set The Pace on Thursday

    Premier Health Group (OTC:PHGRF) (CSE:PHGI), Aceto Corporation (ACET), OPKO Health Inc (OPK), and Midatech Pharma plc (NASDAQ:MTP) represent 4 healthcare stocks to pay attention to on Thursday. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company which is laser-focused on developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies to champion products and services meant to improve the quality of life for consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI) today announced the launch of at technology-enabled mental health counseling service for patients in urban centers and remote and underserved populations.

  • The Wall Street Journal2 months ago

    [$$] Citibank: Windstream Likely to File for Bankruptcy By Mid-March

    Windstream Holdings Inc., the rural broadband provider that recently lost a legal battle with Aurelius Capital Management, is likely to file for bankruptcy by mid-March, a Citibank report said Wednesday....

  • The Wall Street Journal2 months ago

    [$$] Aceto Wins Approval to Tap Bankruptcy Loan

    Judge Vincent Papalia of the U.S. Bankruptcy Court in Newark, N.J., gave Aceto the go-ahead to start using a loan to help it navigate its chapter 11 proceedings. Aceto’s $60 million secured financing package, of which $15 million is available immediately, is being provided by pre-bankruptcy lenders. The interim approval of the financing also includes the “roll-up” of $23 million in revolving loans that the lenders had provided to the company in January to give it liquidity as it began marketing its assets.

  • The Wall Street Journal2 months ago

    [$$] Payless Owner Alden Global Takes Heat From Other Creditors

    Lawyers for creditors of Payless ShoeSource Inc. blasted the hedge fund that took control of the troubled retailer after its first bankruptcy, saying it drove the company back into chapter 11 less than ...

  • The Wall Street Journal2 months ago

    [$$] Generic Drug Company Aceto Files for Bankruptcy

    Corp. has filed for bankruptcy, saying it faces tens of millions of dollars in customer penalties for supply-chain problems, and plans to sell its chemicals business to New Mountain Capital for $338 million. The Port Washington, N.Y.-based company outlined numerous problems leading up to its chapter 11 bankruptcy on Tuesday, including falling revenue and profit, class-action securities litigation, loan-covenant violations, and the termination of government contracts over trade issues. The publicly traded company’s sales were $711.4 million last year, according to a filing in U.S. Bankruptcy Court in Newark, N.J.

  • GlobeNewswire2 months ago

    ACETO Announces Receipt of Nasdaq Notice Due to Delay in Filing Form 10-Q for the Fiscal Quarter Ended December 31, 2018

    PORT WASHINGTON, N.Y., Feb. 20, 2019 -- ACETO Corporation (Nasdaq: ACET), an international company engaged in the development, marketing, sale and distribution of Human Health.

  • GlobeNewswire2 months ago

    ACETO Announces Proposed Sale of its Chemicals Business Assets to New Mountain Capital for $338 million

    ACETO and its U.S. Subsidiaries File Voluntary Chapter 11 Petitions to Facilitate SaleSecures Commitment for Debtor-in-Possession Financing to Support Normal Course.

  • GlobeNewswire3 months ago

    New Research Coverage Highlights NiSource, Callaway Golf, TEGNA, The Manitowoc, CTS, and Aceto — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ACET earnings conference call or presentation 9-Nov-18 2:00pm GMT

    Q1 2019 Aceto Corp Earnings Call

  • Business Wire4 months ago

    Robbins Arroyo LLP: Lawsuit Says Aceto Corporation (ACET) Misled Shareholders

    Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Aceto Corporation (ACET) have sued the company's officers and directors for breaches of their fiduciary duties between August 25, 2017 and April 18, 2018. Aceto develops, markets, sells, and distributes finished dosage form generic pharmaceuticals and nutraceutical products, among other products. According to the complaint, Aceto assured investors that the company's internal controls over financial reporting were effective.

  • Simply Wall St.4 months ago

    Could The Aceto Corporation (NASDAQ:ACET) Ownership Structure Tell Us Something Useful?

    If you want to know who really controls Aceto Corporation (NASDAQ:ACET), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, Read More...

  • Associated Press5 months ago

    Aceto: Fiscal 1Q Earnings Snapshot

    The Port Washington, New York-based company said it had a loss of 59 cents per share. The chemical company posted revenue of $164.4 million in the period. The company's shares closed at $2.03. A year ago, ...

  • GlobeNewswire5 months ago

    ACETO Reports Fiscal 2019 First Quarter Results

    PORT WASHINGTON, N.Y., Nov. 08, 2018 -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health.

  • GlobeNewswire6 months ago

    ACETO Corporation Adopts Rights Plan Designed to Preserve Valuable Net Operating Loss Carryforwards and Other Tax Benefits

    ACETO Corporation (ACET) today announced that its Board of Directors has adopted a tax asset protection rights plan (the “Rights Plan”).  The Rights Plan is designed to preserve ACETO’s net operating loss carryforwards (NOLs) and other significant tax benefits which may be available to reduce potential future tax liabilities. ACETO’s Board determined that the Rights Plan was warranted and in the best interests of all stockholders due to the substantial dollar amount of the NOLs and other tax assets and the importance of these potential benefits for future cash flows.  The Rights Plan is similar to the tax asset protection rights agreements adopted by numerous other public companies seeking to protect their NOLs and other tax benefits.  The Rights Plan and the rights issued under the Rights Plan will expire on November 5, 2021, or on an earlier date if certain events occur, as described more fully in the Rights Plan.

  • ACCESSWIRE6 months ago

    Update: Lawsuit for Investors in Aceto Corporation (NASDAQ: ACET) Shares Announced by Shareholders Foundation

    SAN DIEGO, CA / ACCESSWIRE / October 22, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares Aceto Corporation (NASDAQ: ACET). The plaintiff seeks ...

  • Business Wire6 months ago

    Robbins Arroyo LLP: Aceto Corporation (ACET) Misled Shareholders According to a Recent Lawsuit

    Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Aceto Corporation (ACET) have filed a shareholder action against the company's officers and directors for breaches of their fiduciary duties between August 25, 2017 and April 18, 2018. Aceto develops, markets, sells, and distributes finished dosage form generic pharmaceuticals and nutraceutical products, among other products. According to the complaint, Aceto assured investors that the company's internal control over financial reporting was effective.